| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/1078-0432.CCR-10-1587 |
| P698 | PubMed publication ID | 21098696 |
| P50 | author | Paul M Neilsen | Q39746360 |
| David F. Callen | Q39746373 | ||
| Fares Al-Ejeh | Q41536653 | ||
| Michael P. Brown | Q42068411 | ||
| P2093 | author name string | Kathleen I Pishas | |
| Raman Kumar | |||
| Andreas Evdokiou | |||
| Irene Zinonos | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 494-504 | |
| P577 | publication date | 2010-11-23 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Nutlin-3a is a potential therapeutic for ewing sarcoma | |
| P478 | volume | 17 |
| Q57115778 | Advanced Glycation End Products Increase MDM2 Expression via Transcription Factor KLF5 |
| Q36009999 | Bioinformatics and variability in drug response: a protein structural perspective |
| Q35894540 | Bone Sarcomas in Pediatrics: Progress in Our Understanding of Tumor Biology and Implications for Therapy |
| Q33815063 | Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas |
| Q37869364 | Emerging therapeutic targets for soft tissue sarcoma |
| Q38979977 | Ewing sarcoma inhibition by disruption of EWSR1-FLI1 transcriptional activity and reactivation of p53. |
| Q39113281 | Factors Affecting EWS-FLI1 Activity in Ewing's Sarcoma |
| Q61570969 | Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in wild-type Ewing sarcoma |
| Q35795406 | Heterogeneous Mechanisms of Secondary Resistance and Clonal Selection in Sarcoma during Treatment with Nutlin. |
| Q35919802 | Hydrophobic Interactions Are a Key to MDM2 Inhibition by Polyphenols as Revealed by Molecular Dynamics Simulations and MM/PBSA Free Energy Calculations |
| Q38837564 | Identifying novel therapeutic agents using xenograft models of pediatric cancer |
| Q50200634 | Induction of apoptosis in Ehrlich ascites tumour cells via p53 activation by a novel small-molecule MDM2 inhibitor - LQFM030. |
| Q38767574 | Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program. |
| Q35857060 | Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program. |
| Q36392660 | Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program |
| Q91755518 | MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388) |
| Q41553688 | MDM2 antagonists synergize with PI3K/mTOR inhibition in well-differentiated/dedifferentiated liposarcomas |
| Q34166049 | MDM2, MDMX and p53 in oncogenesis and cancer therapy |
| Q38983373 | Mdm2 protein expression is strongly associated with survival in malignant pleural mesothelioma. |
| Q36361245 | Metformin produces growth inhibitory effects in combination with nutlin-3a on malignant mesothelioma through a cross-talk between mTOR and p53 pathways |
| Q33728193 | MiR-766 induces p53 accumulation and G2/M arrest by directly targeting MDM4. |
| Q34480997 | Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells |
| Q34288205 | Mutant p53 drives invasion in breast tumors through up-regulation of miR-155. |
| Q39460398 | Mutant p53 drives multinucleation and invasion through a process that is suppressed by ANKRD11. |
| Q39421527 | Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a pro-invasive secretome |
| Q39650171 | Potential molecular targets for Ewing's sarcoma therapy |
| Q37290519 | Screening of Pleural Mesotheliomas for DNA-damage Repair Players by Digital Gene Expression Analysis Can Enhance Clinical Management of Patients Receiving Platin-Based Chemotherapy. |
| Q41303735 | Targeting the p53 Pathway in Ewing Sarcoma. |
| Q38108248 | The adolescent and young adult with cancer: state of the art -- bone tumors |
| Q35573610 | The cell cycle regulator CCDC6 is a key target of RNA-binding protein EWS. |
| Q38192005 | The clinical development of p53-reactivating drugs in sarcomas - charting future therapeutic approaches and understanding the clinical molecular toxicology of Nutlins |
| Q38437281 | The importance of being dead: cell death mechanisms assessment in anti-sarcoma therapy. |
| Q37577477 | USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis |
| Q37323049 | Variability in functional p53 reactivation by PRIMA-1(Met)/APR-246 in Ewing sarcoma. |
| Q36618628 | Wild-type and mutant p53 mediate cisplatin resistance through interaction and inhibition of active caspase-9 |
| Q35764901 | XI-006 induces potent p53-independent apoptosis in Ewing sarcoma |
| Q39465507 | miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy |
Search more.